Dear Sir, In their recent For debate article [1] , Kolb and Kolb-Bachofen wish to attract attention to the notion that nitric oxide (NO) rather than free oxygen radicals (FOR) may be involved as a major biochemical mediator of inflammatory islet beta-cell destruction in Type I (insulin-dependent) diabetes mellitus. They argue that interleukin-1 (IL-1) secreted by inflammatory cells in the insulitis infiltrate induces macrophages to produce NO from L-arginine via the inducible form of NO synthase (iNOS), and that NO then kills the beta cells. They also suggest that the modulating effect of IL-1 on glucosestimulated insulin secretion may be mediated through the synthesis of NO by the constitutive form of NO synthase (cNOS) in the beta cell. They further imply that the beta-cell selective toxic action of ILl described in vitro is indirect, dependent upon the ability of IL-1 to stimulate passenger islet macrophages and endothelial cells to produce NO.
Southern and co-workers [2] were the first to implicate NO as a possible effector molecule that mediates IL-l's actions on islets. Their initial observations were later confirmed and extended by severn groups [3] [4] [5] . A critical question is whether IL-1 induces the expression of iNOS in the beta cells or whether this event only happens in passenger macrophages. There are several lines of evidence strongly supporting that NO synthesis is induced in beta cells by IL-I:
1. IL-1 induces expression of iNOS in the hamster insulinoma cell line HIT [6] .
2. Using cyclic GMP (cGMP) accumulation as an assay for NO formation (NO is a potent activator of soluble guanylate cyclase), IL-1 has been demonstrated to induce cGMP accumulation by rat insulinoma RINm5F cells, and this accumulation of cGMP is blocked by NQmonomethyl-L-arginine (NMMA), a synthetic L-arginineanalogue that inhibits NO synthesis [7] . RINm5F cells also have been demonstrated to produce nitrite (an oxidative metabofite of NO) in response to IL-1, and this production is prevented by NMMA [8] .
3. In non-transformed islet beta-cells purified by fluorescence activated cell sorting (FACS), IL-1 induces cGMP accumulation, while IL-1 does not induce cGMP accumulation by FACS purified alpha cells [8] .
4. Using electron paramagnetic resonance spectroscopy IL-1 has been demonstrated to induce the formation of NO by RINm5F cells as evidenced by iron-dithio-dinitrosyI complex formation. It should be noted that this technique has been used to directly demonstrate the formation of NO in a number of cell types including macrophages [8] .
5. Measures that deplete islets of passenger cells (prolonged culture and 95 % 02 atmosphere) do not prevent cytokine mediated betacell damage [9] , and passenger-cell depletion has no effect on the ability of either human or rodent islets to produce NO, as detected by nitrite formation (Corbett et al., unpublished data).
6. The combination of IL-1 and interferon-'r (IFN-T) induces the formation of NO in human islets evidenced by nitrite release and cGMP accumulation, both of which are blocked by NMMA [10] .
Bacterial lipopolysaccharides, IFN-T, tumour necrosis factor-c~ (TNF-c~) and other lymphokines induce iNOS and NO productionin macrophages. In contrast, IL-1 alone or in combination with IFN-Y does not induce NO production by murine macrophages [11] , and to the best of our knowledge IL-1 induced NO production from either human or rat macrophages has yet to be demonstrated. There is little doubt that activated peritoneal macrophages isolated following in vivo activation with Corynebacteriurn parvurn produce NO which mediates islet cell destruction [12] , however: 1) NO produced under these conditions results in non-specific islet cell death (beta-, alpha-, delta-and PP-cell destruction) [13] , while the effects of IL-1 on islet metabolic activity appears to be beta-cell specific; and 2) IL-1 activation of resident islet macrophages, claimed to be the source of IL-1 induced islet NO production, has not been demonstrated. Also it is unknown whether macrophages activated with for example IFN-'F or TNF-a (which may be more relevant stimuli than C.parvurn) will be efficient effectors of islet cell killing.
The involvement of FOR in the pathogenesis of Type 1 diabetes is still an open issue. As shown by Dr. Kolb's group [14] FOR are highly toxic to beta cells. The first suggestion that FOR might be involved in the toxic action of IL-1 was based on the finding that very high concentrations (22 mmol/1) of glucose known to prevent alloxan-induced FOR damage of beta cells also reduced cytokine mediated beta-cell inhibition [9] . The involvement of FOR was later substantiated by the observations that combinations of FOR scavengers partially prevented beta-cell damage in vitro caused by combinations of recombinant cytokines [15] . Attempts have been made to detect FOR directly by electron spin trapping in recombinant IL-1 treated islets, but the amount of tissue that could be produced for these studies was insufficient to create a signal even using alloxan as a positive control (S. Helqvist, personal Communication). However, there is indirect evidence for oxidative stress in islets caused by IL-1 from studies of the pattern of proteins induced by IL-1. IL-1 and hydrogen peroxide, but not heat shock induce the expression of heat shock protein 70 (HSP 70) and haemoxygenase (HO) in islets, but not in thyroid, mesangial or lymphoid cells [16] . This pattern of expression is characteristic, albeit not specific of oxidative stress in other cells [17] . Resistance to IL-1 mediated toxicity is conferred by increasing the islet cell content of HSP-70 [18] and HO [19] . Further, IL-1 induces expression of the FOR scavenging enzyme manganese superoxide dismutase in islets [20] , also suggesting that IL-1 exposed islets mount a protective response against FOR.
In summary, there is strong evidence to suggest that IL-1 directly and selectively causes induction of iNOS and NO production in beta Letters to the editor cells. A role for NO produced by macrophages in the pathogenesis of Type 1 diabetes would be supported if significant induction of iNOS and NO synthesis is caused by relevant stimuli. The role of FOR is far from settled and further studies are needed. NO and FOR can react to form peroxynitrite anion, which rapidly decomposes to hydroxyl anions and nitrogen dioxide [21] , of which the former is a highly reactive and toxic compound. Thus, a complex interplay between NO and FOR may exist.
In conclusion, we would suggest that IL-1 secreted from macrophages in the earliest as well as later phase of the insulitis process induces expression of iNOS and production of NO selectively in beta cells and not in other islet cells, leading to destruction of mitochondrial iron-sulphur containing enzymes, resulting in reduced glucose oxidation, energy production and ultimately beta-cell death. Dear Sir, In interpreting the data from their twin study, Kaprio et al. [1] overlook recent observations that impaired glucose tolerance and Type 2 (non-insulin-dependent) diabetes mellitus in adult life are strongly linked with impaired prenatal growth [2, 3] .
Monozygotic (MZ) twins have a more adverse prenatal environment than dizygotic (DZ) twins. They have lower mean birthweight, higher perinatal mortality rates and a higher prevalence of congenital malformations [4] . These effects are more marked in MZ twins who have a monochorial type of placentation suggesting that they are a result of placental competition for a limited supply of nutrients [5] . A subset of MZ twins characterised by an unusually adverse prenatal environment would be expected to have a high diabetes prevalence. This would lead to higher concordance rates in MZ than DZ twins. It would be interesting to know the true prevalence of diabetes in MZ and DZ twins.
We have previously argued that the influence of maternal nutrition on fetal growth explains the familial clustering of diabetes [2] . It is likely that similarities in fetal nutrition explain a large part of the increased concordance rates of diabetes in MZ twins. Consequently, twin studies may be an mlreliable method of assessing the genetic contribution to Type 2 diabetes.
Yours sincerely, DIW Phillips, CN Hales and DJP Barker
